Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of α-particle-emitting 211At-labeled trastuzumab

Nuclear Medicine and Biology

Volumn 36, Issue 6, 2009, Pages 659-669

  Boskovitz, Abraham ^a   McLendon, Roger E ^a   Okamura, Tatsunori ^a   Sampson, John H ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Astatine 211; HER2; Radioimmunotherapy; Targeted radiotherapy; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TPS3.2 AT 211; TRASTUZUMAB; TRASTUZUMAB AT 211; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LOW DRUG DOSE; NONHUMAN; RADIOIMMUNOTHERAPY; RAT; SURVIVAL TIME;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INJECTIONS, SPINAL; ISOTOPE LABELING; MENINGEAL CARCINOMATOSIS; MICE; RADIOIMMUNOTHERAPY; RATS; RECEPTOR, ERBB-2; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651177582     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.04.003     Document Type: Article

References (37)

1. Prados M.D. Primary neoplasms of the central nervous system in adults. In: Kufe D.W., et al. (Ed). Cancer medicine. 7th ed. (2006), BC Decker, Hamilton, ON 1037-1064
2. Chamberlain M.C. Neoplastic meningitis. J Clin Oncol 23 (2005) 3605-3613
3. Jaeckle K.A. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol 33 (2006) 312-323
4. Press M.F., Cordon-Cardo C., and Slamon D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5 (1990) 953-962
5. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50 (1990) 4087-4091
6. Natali P.G., Nicotra M.R., Bigotti A., et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 45 (1990) 457-461
7. Sliwkowski M.X., Lofgren J.A., Lewis G.D., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 (1999) 60-70
8. Hortobagyi G.N. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 28 (2001) 43-47
9. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 37 Suppl 1 (2001) S18-S24
10. Pestalozzi B.C., and Brignoli S. Trastuzumab in CSF. J Clin Oncol 18 (2000) 2349-2351
11. Platini C., Long J., and Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7 (2006) 778-780
12. Stemmler H.J., Schmitt M., Harbeck N., et al. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15 (2006) 1373-1377
13. Laufman L.R., and Forsthoefel K.F. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2 (2001) 235
14. Stemmler H.J., Mengele K., Schmitt M., et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER-2 overexpressing metastatic breast cancer: a case report. Anticancer Drugs 19 (2008) 832-836
15. Mir O., Ropert S., Alexandre J., Lemare F., and Goldwasser F. High dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2-expressing breast cancer. Annals Oncol 19 (2008) 1978-1980
16. Millar W.T., and Barrett A. Dosimetric model for antibody targeted radionuclide therapy of tumor cells in cerebrospinal fluid. Cancer Res 50 Suppl (1990) 1043s-1048s
17. Vaidyanathan G., and Zalutsky M.R. Astatine radiopharmaceuticals: prospects and problems. Curr Radiopharm 1 (2008) 177-196
18. Zalutsky M.R., Archer G.E., Garg P.K., Batra S.K., and Bigner D.D. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. Nucl Med Biol 23 (1996) 449-458
19. 211At-labeled antibodies for clinical use. J Nucl Med 42 (2001) 1508-1515
20. Benz C.C., Scott G.K., Sarup J.C., et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24 (1993) 85-95
21. Fuchs H.E., Archer G.E., Colvin O.M., et al. Activity of intrathecal 4-hydroperoxycyclo-phosphamide in a nude rat model of human neoplastic meningitis. Cancer Res 50 (1990) 1954-1959
22. Grossi P.M., Ochiai H., Archer G.E., et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Cancer Res 9 (2003) 5514-5520
23. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res 2 (1996) 963-972
24. 2: a case study. Cancer 91 (2001) 1809-1813
25. Kramer K., Humm J.L., Souweidane M.M., et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 25 (2007) 5465-5470
26. Moseley R.P., Benjamin J.C., Ashpole R.D., et al. Carcinomatous meningitis: antibody guided therapy with I-131 HMFG1. J Neurol Neurosurg Psychiatry 54 (1991) 260-265
27. Miederer M., McDevitt M.R., Borchardt P., et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of α-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res 10 (2004) 6985-6992
28. 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol 33 (2006) 333-347
29. Braun S., Hepp F., Sommer H.L., and Pantel K. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 84 (1999) 1-5
30. Bergman I., Burckart G.J., Pohl C.R., et al. Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. J Pharmacol Exp Ther 284 (1998) 111-115
31. Zalutsky M.R., McLendon R.E., Garg P.K., Archer G.E., Schuster J.M., and Bigner D.D. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res 54 (1994) 4719-4725
32. van den Berg M.P., Romeijn S.G., Verhoef J.C., and Merkus F.W.H.M. Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods 116 (2002) 99-107
33. Nopoulos P., Flaum M., and Andreasen N.C. Sex differences in brain morphology in schizophrenia. Am J Psychiatry 154 (1997) 1648-1654
34. 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histological analysis. Int J Radiat Oncol Biol Phys 45 (1999) 491-499
35. 211At-labeled chimeric 81C6 anti-tenascin monoclonal antibody. J Nucl Med 49 (2008) 30-38
36. HER2 antibody fragments for in vivo imaging. Cancer Res 65 (2005) 5907-5916
37. 211At. Nucl Med Biol 30 (2003) 351-359